指南与共识儿科影像胸部DR

新生儿筛查中囊性纤维化诊断不确定婴儿的临床管理与随访指南

Guidelines for the clinical management and follow-up of infants with inconclusive cystic fibrosis diagnosis through newborn screening.
指南 / 共识 · Arch Pediatr · 2017-11-22

法国囊性纤维化学会「新生儿筛查与疑难诊断」工作组制定指南,针对新生儿筛查发现IRT升高但汗液试验和/或CFTR DNA结果不确定的婴儿,明确诊断不确定的定义、初始评估(痰细菌学、胸部放射学、粪便弹性蛋白酶)、随访时间点(3、6、12月龄及此后每年)及重复汗液试验与扩展CFTR测序的时机,以规范管理。

要点

  • 诊断不确定定义为:至多一个CF相关CFTR突变且汗氯30–59mmol/L,或两个CFTR突变(至少一个致病性未知)且汗氯低于60mmol/L。
  • 汗氯试验应在12月龄重复,如可能于6和24月龄重复,并做扩展CFTR测序检测罕见突变。
  • 初始评估应在CF参考中心进行,包括痰细菌学分析、胸部放射学和粪便弹性蛋白酶检测。

核心结论

  • 指南旨在规范诊断不明确婴儿的管理,通过重复汗液试验、扩展CFTR测序和CFTR功能探索提高诊断确定性,并在CF参考中心进行初始评估和定期随访。

研究设计与样本

  • 由法国囊性纤维化学会「新生儿筛查与疑难诊断」工作组制定的指南,原文未报告证据分级方法与纳入文献范围。

诊断标准与关键数值

  • 诊断不确定标准一:至多一个CF相关CFTR突变且汗氯值30–59mmol/L。
  • 诊断不确定标准二:两个CFTR突变且至少一个致病性未知,汗氯浓度低于60mmol/L。
  • 汗氯试验重复时机:12月龄,如可能于6和24月龄。
  • 随访时间点:CF参考中心于3、6、12月龄及此后每年随访。

临床应用与阅片要点

  • 初始评估应在CF参考中心进行,包括痰细菌学分析、胸部放射学和粪便弹性蛋白酶检测。
  • 负责患者的初级保健医生应熟悉CF现行管理并与CF中心协作。
  • 任何提示CF的症状均需立即重新评估诊断。
  • 诊断不明确时,CFTR功能探索可能有助于更好理解CFTR功能障碍。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Neonatal screening for cystic fibrosis (CF) can detect infants with elevated immunoreactive trypsinogen (IRT) levels and inconclusive sweat tests and/or CFTR DNA results. These cases of uncertain diagnosis are defined by (1) either the presence of at most one CF-associated cystic fibrosis transmembrane conductance regulator (CFTR) mutation with sweat chloride values between 30 and 59mmol/L or (2) two CFTR mutations with at least one of unknown pathogenic potential and a sweat chloride concentration below 60mmol/L. This encompasses various clinical situations whose progression cannot be predicted. In these cases, a sweat chloride test has to be repeated at 12 months, and if possible at 6 and 24 months of life along with extended CFTR sequencing to detect rare mutations. When the diagnosis is not definite, CFTR functional explorations may provide a better understanding of CFTR dysfunction. The initial evaluation of these infants must be conducted in dedicated CF reference centers and should include bacteriological sputum analysis, chest radiology, and fecal elastase assay. The primary care physicians in charge of these patients should be familiar with the current management of CF and should work in collaboration with CF centers. A follow-up should be performed in a CF reference center at 3, 6, and 12 months of life and every year thereafter. Any symptom indicative of CF requires immediate reevaluation of the diagnosis. These guidelines were established by the "neonatal screening and difficult diagnoses" working group of the French CF society. Their objective is to standardize the management of infants with unclear diagnosis.

来源:Arch Pediatr,查看原文。版权归原作者所有。

引用

  1. Sermet-Gaudelus I, Brouard J, Audrézet MP, et al. Guidelines for the clinical management and follow-up of infants with inconclusive cystic fibrosis diagnosis through newborn screening. Arch Pediatr. 2017. PMID: 29174009. doi:10.1016/j.arcped.2017.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。